In this episode, Dr. Bret Bucklen discusses a new report released by his team this month, which is a cost-benefit analysis of the use of Medication-Assisted Treatment (MAT). The study compares the benefit-to-cost ratio for four different types of MATs that are currently used by the PA Department of Corrections: Revia, Vivitrol, Suboxone, and Sublocade. Revia (pill form) and Vivitrol (shot form) are referred to as “antagonist” MATs; Suboxone (pill form) and Sublocade (shot form) are referred to as “partial agonist” MATs. How do the costs (including the potential cost of diversion in prison) and benefits (including recidivism reduction and overdose death reduction) stack up for these various forms of MAT? This episode explains what MAT is, how it is used within the department, and the results from this new cost-benefit analysis study.
Podcast: Play in new window | Download